LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

DexCom Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

69.73 1.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

68.85

Max

71.01

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-68M

200M

Pardavimai

-68M

1.2B

P/E

Sektoriaus vid.

32.411

49.712

Pelnas, tenkantis vienai akcijai

0.56

Pelno marža

16.738

Darbuotojai

11,000

EBITDA

-52M

337M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+21.3% upside

Dividendai

By Acuity

Kitas uždarbis

2026-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.9B

29B

Ankstesnė atidarymo kaina

68.54

Ankstesnė uždarymo kaina

69.73

Naujienos nuotaikos

By Acuity

33%

67%

83 / 342 reitingas Healthcare

DexCom Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Apie bendrovę DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat